Mass Spectrometry for Peptide Identity Confirmation

A peptide COA typically includes two categories of analytical result that are often misread as equivalent: identity and purity. They are not. Purity, measured by HPLC, characterises the relative proportion of the principal compound in the sample compared to all UV-absorbing species detected. Identity, confirmed by mass spectrometry, addresses a different and logically prior question: is the compound in the vial the one claimed on the label?

The distinction matters because both tests can pass while the other fails. A sample can be highly pure - consisting almost entirely of a single compound - while that compound is not the intended peptide. Conversely, a sample can contain the correct compound at relatively lower purity due to synthesis-related impurities. Identity testing does not assess purity, and purity testing does not confirm identity. A complete analytical record for a research peptide requires both.

Mass spectrometry has become the standard tool for peptide identity confirmation in part because it is highly specific and relatively rapid. The molecular mass of a peptide is determined by its amino acid sequence and can be calculated from first principles. If the observed mass matches the theoretical mass within the instrument's measurement tolerance, the result supports identity - with the caveats around isomers and sequence variants discussed later in this guide.

The theoretical mass of a peptide is calculated by summing the residue masses of each amino acid in the sequence and adding the mass of water - one molecule is consumed at each peptide bond during synthesis, but the intact peptide retains the contribution of water at its termini. For a short peptide of five to ten residues this calculation is straightforward; for longer or modified peptides the bookkeeping becomes more involved but the principle is the same.

The observed mass is what the mass spectrometer measures for the sample. Depending on the instrument and method, this is typically expressed as a mass-to-charge ratio (m/z) from which the actual mass is calculated. For a high-resolution instrument, the agreement between theoretical and observed mass is expected to within a few millida ltons. Lower-resolution instruments tolerate a somewhat wider window, and the COA should state the method and the instrument type so the reader can assess whether the reported agreement is within a normal performance range.

The numerical agreement is necessary but not sufficient evidence of identity. Two peptides with different sequences can share the same nominal mass if their residue compositions happen to sum to the same value - for example, leucine and isoleucine are isobaric at the same resolution most mass spectrometers use for intact peptide analysis. A mass match is therefore strong evidence, not proof, of identity. Where the consequence of a misidentification would be significant, orthogonal methods such as amino acid analysis or tandem mass spectrometry provide additional confidence.

Two mass conventions are routinely used in peptide analytical work, and mixing them produces errors that can appear to indicate a failed identity test when none exists. Monoisotopic mass is calculated using the mass of the most abundant stable isotope of each element - for carbon this is carbon-12, for hydrogen it is hydrogen-1, and so on. Average mass is calculated using the natural isotopic abundances of all stable isotopes, weighted accordingly.

For small molecules and short peptides, the difference between monoisotopic and average mass is small but not negligible - it typically falls in the range of a fraction of a dalton to several daltons depending on the number of atoms. For larger peptides, the difference grows. When comparing a reported observed mass against a calculated theoretical mass, both values must use the same convention. A COA that reports the observed mass without specifying whether it is monoisotopic or average is ambiguous.

High-resolution instruments operating under electrospray conditions can typically resolve the isotope envelope of a peptide, allowing the monoisotopic peak to be clearly identified. Lower-resolution instruments, including many time-of-flight instruments used in rapid quality control settings, report an average of the envelope rather than a resolved monoisotopic peak. Knowing which regime applies determines which mass calculation to use when evaluating the identity result on a COA.

The most commonly used ionisation method for peptide identity work in a quality control setting is electrospray ionisation, or ESI. In this technique, the peptide is dissolved in an acidic aqueous-organic solvent and sprayed through a charged needle, generating a fine mist of highly charged droplets that evaporate to yield gas-phase ions. These ions carry multiple positive charges - typically by accepting protons at basic residues and at the N-terminus - which is the defining characteristic of ESI.

Because ESI generates multiply charged ions, the instrument records a series of peaks corresponding to the same compound carrying different numbers of charges. A peptide with an observed neutral mass of 3000 daltons might appear in the spectrum as a peak at approximately m/z 1001 (charge state +3), m/z 751 (charge state +4), and m/z 601 (charge state +5). The actual molecular mass is recovered by the formula: mass = (m/z × z) minus z, where z is the number of protons added. Most software performs this deconvolution automatically and reports the neutral mass directly.

Understanding charge states matters when reading a COA because the m/z value reported for the observed peak cannot be compared directly to the theoretical molecular mass. If a COA lists the observed m/z and the charge state, the neutral mass can be verified by hand. If it lists only the m/z without the charge state, the result cannot be independently evaluated. A COA reporting a deconvoluted neutral mass is the clearest format.

When a mass spectrometry result shows a discrepancy from the expected theoretical mass, the magnitude and direction of the difference often point to a specific chemical explanation. The most common is oxidation, which adds approximately 16 daltons to the measured mass and occurs most readily at methionine, cysteine, and tryptophan residues. A shift of plus 16 daltons in a peptide containing one of these residues is a strong indicator of oxidative modification, which may have occurred during synthesis, purification, or storage.

Salt adducts are another frequent source of discrepancy. Sodium adds approximately 22 daltons relative to a proton, and potassium adds approximately 38 daltons. When a peptide is analysed from a solution containing trace sodium or potassium - common in laboratory solvents and glassware - adduct ions appear alongside or instead of the protonated species. A mass shift of plus 22 or plus 38 daltons that disappears when the sample is prepared in high-purity solvents is almost certainly a sodium or potassium adduct rather than a modification of the peptide itself.

Incomplete synthesis produces deletion sequences - peptides in which one or more amino acids were not incorporated during solid-phase assembly. These appear as peaks at masses lower than the expected molecular weight by the mass of the missing residue. A deletion of one alanine residue, for example, shifts the mass by approximately 71 daltons. Multiple deletions produce a characteristic ladder of peaks below the principal species in the spectrum, which is informative about synthesis quality even if the majority of material is correctly assembled.